Technological advancements in cell line engineering (gene editing tools) & cell line development technologies, screening technologies and process development are giving immense growth opportunities for the market
This report covers all segments, global trends and emerging strategies of the outsourcing market related to drug discovery, preclinical development, clinical phases and commercial manufacturing of biologics.
Increasing need in emerging markets, production of radiopharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radioisotopes and replacement of old/traditional equipment are the opportunities likely to propel the growth of the nuclear medicine market.
The contract biomanufacturing global market is driven by the increasing trend of outsourcing among the biopharmaceutical companies, availability of advanced bioprocessing capabilities among the contract bioservice providers and the escalating approval and adoption of biologics and the cost effective biosimilars among the value centric global patient pool leading to huge volume demand for biologics
The factors such as increased radioisotopes applications, rise in public awareness, use of SPECT/CT and PET/CT imaging scans, abundance of radiopharmaceuticals, advancements in imaging technology (hybrid imaging), production of radiopharmaceuticals from cyclotrons are driving the market.
Nonalcholic Steatohepatitis (NASH) Also Known As “Fatty Liver” Causes Inflammation And Damages Liver By Accumulating Fat In People Who Do Not Abuse Alcohol, If Untreated This Leads To Cirrhosis. This Pipeline Analysis Gives Comprehensive Insights On Various Drugs Being Developed.
IQ4I Research & Consultancy published a new report on - Drug Discovery Outsourcing (DDO) Global Market - Forecast To 2027 analyzes and studies the major competition, market drivers & Opportunities, Restraints & Threats in North America, Europe, Asia-Pacific and Rest of the World, spread through 210 slide.
Small molecules continue to dominate the global therapeutics market, many molecules going off-patent is paving way for introduction of generics creating a favorable opportunity for the Pharmaceutical contract manufacturers.